Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
68
PASG Quote, Financials, Valuation and Earnings
Last price:
$10.10
Seasonality move
:
20.53%
Day range:
$8.23 - $9.31
52-week range:
$5.12 - $20.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.92x
Volume:
91.7K
Avg. volume:
41.7K
1-year change:
-35.14%
Market cap:
$28.7M
Revenue:
--
EPS (TTM):
-$9.75
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PASG
Passage Bio, Inc.
|
-- | -$2.97 | -- | -31.77% | $39.60 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $7.00 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PASG
Passage Bio, Inc.
|
$9.21 | $39.60 | $28.7M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.21 | $0.85 | $152.5M | 2.03x | $0.80 | 0% | 2.35x |
|
NNVC
NanoViricides, Inc.
|
$1.23 | $7.00 | $22.1M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.88 | $2.00 | $727K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.23 | $7.00 | $7.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PASG
Passage Bio, Inc.
|
43.89% | 4.762 | 97.13% | 2.37x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PASG
Passage Bio, Inc.
|
-$200K | -$8.7M | -60.27% | -90.51% | -- | -$4.9M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Passage Bio, Inc. vs. Competitors
-
Which has Higher Returns PASG or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Passage Bio, Inc.'s net margin of -255.85%. Passage Bio, Inc.'s return on equity of -90.51% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital PASGPassage Bio, Inc.-- -$2.44 $55.5M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About PASG or NBY?
Passage Bio, Inc. has a consensus price target of $39.60, signalling upside risk potential of 329.97%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Passage Bio, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Passage Bio, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PASGPassage Bio, Inc.6 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is PASG or NBY More Risky?
Passage Bio, Inc. has a beta of 1.859, which suggesting that the stock is 85.889% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock PASG or NBY?
Passage Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Passage Bio, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PASG or NBY?
Passage Bio, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Passage Bio, Inc.'s net income of -$7.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Passage Bio, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Passage Bio, Inc. is -- versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PASGPassage Bio, Inc.-- -- -- -$7.7M NBYNovaBay Pharmaceuticals, Inc.2.35x 2.03x $521K -$1.3M
-
Which has Higher Returns PASG or NNVC?
NanoViricides, Inc. has a net margin of -- compared to Passage Bio, Inc.'s net margin of --. Passage Bio, Inc.'s return on equity of -90.51% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital PASGPassage Bio, Inc.-- -$2.44 $55.5M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About PASG or NNVC?
Passage Bio, Inc. has a consensus price target of $39.60, signalling upside risk potential of 329.97%. On the other hand NanoViricides, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 469.11%. Given that NanoViricides, Inc. has higher upside potential than Passage Bio, Inc., analysts believe NanoViricides, Inc. is more attractive than Passage Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PASGPassage Bio, Inc.6 0 0 NNVCNanoViricides, Inc.0 0 0 -
Is PASG or NNVC More Risky?
Passage Bio, Inc. has a beta of 1.859, which suggesting that the stock is 85.889% more volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock PASG or NNVC?
Passage Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Passage Bio, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PASG or NNVC?
Passage Bio, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Passage Bio, Inc.'s net income of -$7.7M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Passage Bio, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Passage Bio, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PASGPassage Bio, Inc.-- -- -- -$7.7M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns PASG or OGEN?
Oragenics, Inc. has a net margin of -- compared to Passage Bio, Inc.'s net margin of --. Passage Bio, Inc.'s return on equity of -90.51% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital PASGPassage Bio, Inc.-- -$2.44 $55.5M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About PASG or OGEN?
Passage Bio, Inc. has a consensus price target of $39.60, signalling upside risk potential of 329.97%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 126.37%. Given that Passage Bio, Inc. has higher upside potential than Oragenics, Inc., analysts believe Passage Bio, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PASGPassage Bio, Inc.6 0 0 OGENOragenics, Inc.1 0 0 -
Is PASG or OGEN More Risky?
Passage Bio, Inc. has a beta of 1.859, which suggesting that the stock is 85.889% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock PASG or OGEN?
Passage Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Passage Bio, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PASG or OGEN?
Passage Bio, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Passage Bio, Inc.'s net income of -$7.7M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Passage Bio, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Passage Bio, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PASGPassage Bio, Inc.-- -- -- -$7.7M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns PASG or PTN?
Palatin Technologies has a net margin of -- compared to Passage Bio, Inc.'s net margin of --. Passage Bio, Inc.'s return on equity of -90.51% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PASGPassage Bio, Inc.-- -$2.44 $55.5M PTNPalatin Technologies-- -- -- -
What do Analysts Say About PASG or PTN?
Passage Bio, Inc. has a consensus price target of $39.60, signalling upside risk potential of 329.97%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Passage Bio, Inc., analysts believe Palatin Technologies is more attractive than Passage Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PASGPassage Bio, Inc.6 0 0 PTNPalatin Technologies0 0 0 -
Is PASG or PTN More Risky?
Passage Bio, Inc. has a beta of 1.859, which suggesting that the stock is 85.889% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock PASG or PTN?
Passage Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Passage Bio, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PASG or PTN?
Passage Bio, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Passage Bio, Inc.'s net income of -$7.7M is higher than Palatin Technologies's net income of --. Notably, Passage Bio, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Passage Bio, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PASGPassage Bio, Inc.-- -- -- -$7.7M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns PASG or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Passage Bio, Inc.'s net margin of --. Passage Bio, Inc.'s return on equity of -90.51% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital PASGPassage Bio, Inc.-- -$2.44 $55.5M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About PASG or TOVX?
Passage Bio, Inc. has a consensus price target of $39.60, signalling upside risk potential of 329.97%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3004.21%. Given that Theriva Biologics, Inc. has higher upside potential than Passage Bio, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Passage Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PASGPassage Bio, Inc.6 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is PASG or TOVX More Risky?
Passage Bio, Inc. has a beta of 1.859, which suggesting that the stock is 85.889% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock PASG or TOVX?
Passage Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Passage Bio, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PASG or TOVX?
Passage Bio, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Passage Bio, Inc.'s net income of -$7.7M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Passage Bio, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Passage Bio, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PASGPassage Bio, Inc.-- -- -- -$7.7M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
50
TGL alert for Dec 8
Treasure Global, Inc. [TGL] is up 7.35% over the past day.
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 47.5% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 10.15% over the past day.
